Advanced search
Publication Cover
Expert Opinion on Drug Safety Volume 2, 2003 - Issue 3
Submit an article Journal homepage
439
Views
55
CrossRef citations to date
0
Altmetric
Review

Antidepressant-induced hepatotoxicity

M Isabel Lucena Servicio de Farmacología Clínica, Unidad de Hepatología, Hospital Universitario, Facultad de Medicina, Universidad de Málaga, Spain
,
Alfonso Carvajal Instituto de Farmacoepidemiología, Facultad de Medicina, Ramón y Cajal, 7 47005 Valladolid, Spain. [email protected]
,
Raúl J Andrade Instituto de Farmacoepidemiología, Facultad de Medicina, Ramón y Cajal, 7 47005 Valladolid, Spain. [email protected]
&
Alfonso Velasco Departamento de Biología Celular y Farmacología de la Universidad de Valladolid, Spain
Pages 249-262 | Published online: 03 Mar 2005

Bibliography

  • BRENT DA, BIRMAHER B: Adolescentdepression. N Engl. J. Med. (2002) 347:667–671.
  • DORIS A, EBMEIER K, SHAJAHAN P:Depressive illness. Lancet (1999) 354:1369–1375.
  • GLASS RM: Depression. A call for papers. JAMA (2002) 288:1400–1401.
  • HALE AS: New antidepressants: use in high-risk patients. J. Clar. Psychiatry (1993) 54\(Suppl. 8):61–73.
  • CARNEY RM, JAFFE AS: Treatment of depression following acute myocardial infarction. JAMA (2002) 288:750–751.
  • RICHELSON E: Pharmacology of antidepressants. Mayo OM Proc. (2001) 76:511–527.
  • ••A comprehensive review of all aspects of thepharmacology of antidepressants.
  • MURRAY CJL, LOPEZ AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet (1997) 349:1498–1504.
  • US PREVENTIVE SERVICES TASK FORCE: Screening for depression: recommendations and rationale. Ann. Intern. Med. (2002) 136:760–764.
  • CARNE X, MASSANA J: [A 'happy world]. Med. Clin. (Barr) (2001) 116:335-336. Spanish.
  • ALONSO MP, DE ABAJO FJ, MARTINEZ JJ, MONTERO D, MARTIN-SERRANO G, MADURGA M: [Evolution of antidepressive drug consumption in Spain. The impact of selective serotonin re-uptake inhibitors]. Med. Clar. (Barc) (1997) 108:161-166. Spanish.
  • MOURILHE P, STOKES PE: Risks and benefits of selective serotonin re-uptake inhibitors in the treatment of depression. Drug Sal (1998) 18:57–82.
  • FULTON B, BENFIELD P: Moclobemide. An update of its pharmacological properties and therapeutic use. Dugs (1996) 52:450–474.
  • ROSHOLM JU, GRAM LF, ISACSSON G,HALLAS J, BERGMAN U: Changes in the pattern of antidepressant use upon the introduction of the new antidepressants: a prescription database study. Eur. I Clar. Pharmacol (1997) 52:205–209.
  • ANDERSON IM: Selective serotonin re-uptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord. (2000) 58:19–36.
  • ZIMMERMAN HJ: Hepatotoxicity. In: The Adverse Effects of Drugs and Other Chemicals on the Liver (2nd edri). Lippincott Williams & Wilkins, Philadelphia (1999).
  • ••The most comprehensive overview on DILD.
  • LUCENA MI, CAMARGO R, ANDRADE RJ, HIDALGO R, SANCHEZ DE LA CUESTA F: Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology (2001) 33:123–130.
  • •This study demonstrates the better performance of the Council of International Organizations of Medical Sciences (CIOMS) scale in the assessment of hepatotoxicity.
  • SELIMK, KAPLOWITZ N: Hepatotoxicity of psychotropic drugs. Hepatology (1999) 29:1347–1351.
  • REPORT OF AN INTERNATIONAL CONSENSUS MEETING: Criteria of drug-induced liver disorders. J. Hepatol (1990) 11:272–276.
  • MAILLE F, DUVOUX C, CHERQUI D, RADIER C, ZAFRANI E-S, DHUMEAUX D: [Auxiliary hepatic transplantation in iproniazid-induced subfulminant hepatitis. Should iproniazid still be sold in France?]. Gastroeriterol Clar. Biol. (1999) 23:1083-1085. French.
  • ROSENBLUM LE, KORN RJ, ZIMMERMAN H: Hepatocellular jaundice as a complication of iproniazid therapy. Arch. Intern. Med. (1960) 105:115–125.
  • DJIBO A, LAWAN A: Behavioral disorders after treatment with isoniazid. Bull. Soc. Pathol Exot. (2001) 94:112–114.
  • NELSON SD, MITCHEL JR, TIMBRELL JA et al.: Isoniacid and iproniazid: activation of metabolites to toxic intermediates in man and rat. Science (1976) 193:901–903.
  • HOMBERG JC, STELLY M, ANDREIS I, ABUAF N, SAADOUN F, ANDRE J: A new antimitochondrial antibody (anti-M6) in iproniazid-induced hepatitis. Clar. Exp. Immurrol (1982) 47:93–103.
  • PESSAYRE D: Role of reactive metabolites in drug-induced hepatitis. J. Hepatol (1995) 23\(Suppl. 1):16–24.
  • BLONKOVSKY HL, BLANCHETTE PL, SCHNED AR: Severe liver injury due to phenelzine with unique hepatic deposition of extracellular material. Am. J. Med. (1986) 80:689–692.
  • GOMEZ-GIL E, SALMERON JM, MAS A: Phenelzine-induced fulminant hepatic failure. Ann. Intern. Med. (1996) 124:692–693.
  • BANDT C, HOFFBAUER FW: Liver injury associated with tranylcipromine therapy. JAMA (1964) 188:752.
  • TIMMINGS P, LAMONT D: Intrahepatic cholestasis associated with moclobemide leading to death. Lancet (1996) 347:762–763.
  • GARCIA-DIAZ J, GILA A, FRAGUAS C, CASTILLO I: Hepatitis colestasica asociada con el uso de moclobemida. Med. Clar. (Barr) (1998) 11:77.
  • KLERMAN GL, COLE JO: Clinical pharmacology of imipramine and related antidepressants compounds. Pharmacol Rev. (1965) 17:101–141.
  • HOLT C, CSETE M, MARTIN P: Hepatotoxicity of anesthetics and other central nervous system drugs. Gastroeriterol Clar. North Am. (1995) 24:853–873.
  • HORST DA, GRACE ND, LECOMPTE PM: Prolonged cholestasis and progressive hepatic fibrosis following imipramine therapy. Gastroenterology (1980) 79:550–554.
  • SCHAEFER MS, EDMUNDS RS, MARKIN RP et al: Hepatic failure associated with imipramine therapy. Pharmacotherapy (1990) 10:66–69.
  • LLAN Y, SAMUEL D, REYNES M, TUR-KASPA R: Hepatic failure associated with imipramine therapy. Pharmacopsychiatry (1996) 29:79–80.
  • PRICE LH, NELSON JC, WALTRIP RW: Desipramine-associated hepatitis. J. Clirr. Psychopharmacol (1983) 3:243–246.
  • POWELL WJ Jr, KOCH-WESSER J, WILLIAM RA: Lethal hepatic necrosis after therapy with imipramine and desipramine. JAMA (1968) 206:642–645.
  • HOLMBERG MB, JANSSON B: A study of blood count and serum transaminase in prolonged treatment with amitryptiline. J. New Drugs (1962) 2:361–365.
  • FARRELL GC: Drug-induced liver disease. Churchill-Livingstone, London (1994):345–346.
  • •An excellent textbook covering all relevant aspects of DILD. Gastroenterol Chu. Biol. (1982) 6:915–918.
  • MORGAN DH: Jaundice associated withamitriptyline. Br. J. Psychiatry (1969) 115:105–106.
  • YON J, ANURAS S: Hepatitis caused by amitryptiline therapy. JAMA (1975) 232:833–834.
  • CUNNINGHAM ML: Acute hepatic necrosis following treatment with amitriptyline and diazepam. Br J. Psychiatry (1965) 111:1107–1109.
  • DANAN G, BERNAU J, MOULLOT X et al: Amitriptyline-induced fulminant hepatitis. Digestion (1984) 30:179–184.
  • ANDERSON BM, HENRIKSON IR: Jaundice and eosinophilia associated with amitriptyline. j Chu. Psychiatry (1978) 39:730–731.
  • PEDERSEN AM, ENEVOLDSEN HK: Nortriptyline-induced hepatic failure. Ther. Drug Mond. (1996) 18:100–102.
  • KELLY C, ROCHE S, NAGUIB M, WEBB S, ROBERTS M, PITT B: A prospective evaluation of the hepatotoxicity of lofepramine in the elderly. Int. Chu. Psychopharmacol (1993) 8:83–86.
  • KEEGAN AD: Doxepin-induced recurrentacute hepatitis. Aust. NZ J. Med. (1993) 23:523.
  • VAN VLIET AC, FRENKEL M, WILSON JH: Acute liver necrosis after treatment with opipramol. Ned. Tljdschr. Gerreeskd. (1977) 121:1325–1327.
  • BRAUN JS, GEIGER R, WEHNER H et al: Hepatitis caused by antidepressive therapy with maprotiline and opipramol. Pharmacopsychiatry (1998) 31:152–155.
  • PATTERSON JF: Amoxapine associated with hepatotoxicity. I Chu. Psychopharmacol (1987) 7:50–51.
  • MANAPANY M, MARCHETTI B, BERTRAND-LEPENSEC D et al: [Acute cytolytic hepatitis caused by amoxapine]. Gastroenterol. Chu. Biol. (1993) 17:405-406. French.
  • LARREY D, BERSON A, HABERSETZER F et al.: Genetic predisposition to drug hepatotoxicity: role in hepatitis caused by amineptine, a tricyclic antidepressant. Hepatology (1989) 10:168–173.
  • ••A seminal paper focusing on mechanismsunderlying predisposition to amineptine-induced liver toxicity.
  • MARTIN D, BONNET PM, MARTIN C et al: [Hepatitis and amineptin]. Chu. Biol. (1981) 5:1071-1072. French.
  • ANDRIEU J, DOLL J, COFFINIER C: [Hepatitis due to amineptin. 4 cases]. Gastroenterol. Clin. Biol. (1982) 6:915-918. French.
  • IMBERT Y, DUCOS P, GRIERE G et al: [Chronic clrrhogenic hepatitis caused by amineptin (Survector)?]. Gastroenterol. Clin. Biol. (1985) 9:747-748. French.
  • RICCA-ROSSELINI S, GRILLI F, GAUDIO M et al.: Hepatic injury associated with amineptine therapy. Ital. J. Gastroenterol. (1990) 22:40–43.
  • JON VILLE A1 DUTERTRE JP, AUTRET E: [Immediate acute hepatic cytolysis after the administration of a single amineptin tablet]. Gastroenterol. Clin. Biol. (1992) 16:368-376. French.
  • LAZAROS GA, STAVRINOS C, PAPATHEODORIDIS GV et al: Amineptine induced liver injury. Report of 43:1015-1019.
  • PESSAYRE D: Physiopathologie des hépatopathies médicamenteuses. Gastroenterol Chu. Biol. (1993) 17:H3–H17.
  • ROBIN M-A, LE ROY M, DESCATOIRE V, PESSAYRE D:
  • •• Plasma membrane cytochromes P450 as neoantigens and autoimmune targets in drug-induced hepatitis. J. Hepatol (1997)
  • LARREY D, TINEL M, LETTERON P et al.: Metabolic activation of the new
  • LE BRICQUIR Y, LARREY D, BLANC P, studies by the author with tianeptine.
  • FROMENTY B, FRENEAUX E, LABBE G et al.: Tianeptine, a new tricyclic antidepressant metabolized by 13-oxidation of its hepatonoic side chain, inhibits the mitochondrial oxidation of medium and short chain fatty acids in mice. Biochem. Pharmacol (1989) 38:3743–3751.
  • BALLEYGUIER C, STERIN D, ZIOL M, TRINCHET JC: Acute mixed hepatitis caused by tianeptine. Gastroenterol Chu. Biol. (1996) 20:607-608. KAPLOWITZ N: Biochemical and cellular mechanisms of toxic liver injury. Semirr. Liver Dis. (2002) 22:137-144. An updated overview of the mechanism of DILD.
  • KAPLOWITZ N: Biochemical and cellular mechanisms of toxic liver injury. Semin. Liver Dis. (2002) 22:137-144.65. ALDERMAN CP, ATCHISON MM, MCNEECE JI: Concurrent agranulocytosis and hepatitis secondary to clomipramine therapy. Br. J. Psychiatry (1993) 162:688–689.
  • •• An updated overview of the mechanism of DILD.
  • ALDERMAN CP, ATCHISON MM, MCNEECE JI: Concurrent agranulocytosis and hepatitis secondary to clomipramine therapy. Br. J. Psychiatry (1993) 162:688–689.
  • ABERNATHY CO, LUKACS L, ZIMMERMAN HJ: Toxicity of tricyclic antidepressants to isolated rat hepatocytes. Biochem. Pharmacol (1975) 24:347–350.
  • BERSON A, FRENAUX E, LARREY D et al: Possible role of the HLA haplotype in hepatotoxicity: an exploratory study in 71 patients with drug-induced idiosyncratic hepatitis. J. Hepatol (1994) 20:336–342.
  • •An approach to the understanding of the genetic basis of hepatotoxicity.
  • MACES, TAYLOR D: Selective serotonin re-uptake inhibitors: a review of efficacy and tolerability in depression. Expert Opin. Pharmacother. (2000) 1:917-933. CACCIA S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Chu. Pharmacokinet. (1998) 34:281-302. A thorough analysis of the different metabolic pathways that follow antidepressants and its genetic influences. COOPER GL: The safety of fluoxetine - an update. Br J. Psychiatry (1988) 153\(Suppl. 3):77–86. MARS F, DUMAS DE LA ROQUE G, GOISSEN P: [Acute hepatitis during treatment with fluoxetine]. Gastroenterol Chu. Biol. (1991) 15:270-271. French. BOBICHON R, BERNARD G, MION F: [Acute hepatitis during treatment with fluoxetine]. Gastroenterol Chu. Biol. (1993) 17:406-407. French.
  • CACCIA S: Metabolism of the newer antidepressants. An overview of the pharmacological and pharmacokinetic implications. Clin. Pharmacokinet. (1998) 34:281–302.
  • •• A thorough analysis of the different metabolic pathways that follow antidepressants and its genetic influences.
  • COOPER GL: The safety of fluoxetine – an update. Br. J. Psychiatry (1988) 153\(Suppl. 3):77–86.
  • MARS F, DUMAS DE LA ROQUE G, GOISSEN P: [Acute hepatitis during treatment with fluoxetine]. Gastroenterol. Clin. Biol. (1991) 15:270-271. French.
  • BOBICHON R, BERNARD G, MION F: [Acute hepatitis during treatment with fluoxetine]. Gastroenterol. Clin. Biol. (1993) 17:406-407. French.
  • FRIEDENBERG FK, ROTHSTEIN KD: Hepatitis secondary to fluoxetine treatment. Am. J. Psychiatry (1996) 153:580.
  • COSME A, BARRIO J, LOBO C, GIL I,CASTIELLA A, ARENAS JI: Acute cholestasis by fluoxetine. Am. J. Gastroenterol (1996) 91:2449–2450.
  • JOHNSTON DE, WHEELER DE: Chronic hepatitis related to use of fluoxetine. Am. J. Gastroenterol. (1997) 92:1225–1226.
  • CAI Q, BENSON MA, TALBOT TJ et al.: Acute hepatitis due to fluoxetine therapy. Mayo Chu. Proc. (1999) 74:692–694.
  • HEMERYCK A, BELPAIRE FM: Selective serotonin re-uptake inhibitors and cytochrome P450 mediated drug-drug interactions: an update. Curr. Drug Metab. (2002) 3:13–37.
  • CAPELLA D, BRUGUERA M, FIGUERAS A, LAPORTE JR: Fluoxetine-induced hepatitis: why is postmarketing surveillance needed? Eur. j Clin. Pharmacy]. (1999) 55:545–546.
  • DUNBAR GC: A comparison of paroxetine, imipramine and placebo in depressed outpatients. Br 1. Psychiatry (1991) 159:394–398.
  • HELMCHEN C, BOERNER RJ, MEYENDORF R, HEGERL U: Reversible hepatotoxicity of paroxetine in a patient with mayor depression. Pharmacopsychiatry (1996) 29:223–226.
  • DE MAN RA: Severe hepatitis attributed to paroxetine (Seroxat). Ned. Thilschr. Ceneeskd. (1997) 141:540–542.
  • ODEH M, MISSELEVECH I, BOSS JH, OLIVEN A: Severe hepatotoxicity with jaundice associated with paroxetine. Am. J. Castroenterol. (2001) 96:2494–2496.
  • BENBOW SJ, GILL G: Paroxetine and hepatotoxicity. Br Med. 1 (1997) 314:1387.
  • LOPEZ- TORRES E, LUCENA MI, SEOANE J, VERGE C, ANDRADE RJ: Citalopram, a new instance of hepatotoxicity related to SSRI. Am. 1 Psychiatry (2003). In Press.
  • FREDRICSON OK, SVENDSEN 0: Hepatotoxicity of citalopram in rats and first-pass metabolism. Arch. Taxied. Suppi. (1978) 1:177–180.
  • MENON RR, HOWARD R: Sertraline andliver toxicity in the elderly. Int. I Ceriatr. Psychiatry (1994) 9:332–334.
  • HAUTEKEETE ML, COLLE I, VAN VLIERBERGHE H, ELEWAUT A: Symptomatic liver injury probably related to sertraline. Castroenterol Clin Biol. (1998) 22:364–365.
  • LAM KS, BLANCHI A, CHAVAILLON JM: [Hepatitis probably secondary to the massive ingestion of fluvoxamine]. Castroenterol Clin. Biol. (1988) 12:398-399. French.
  • PRUDENT A, MARCHETTI B, PIGNOL D et al.: [Acute benign hepatitis probably due to maprotiline]. Castroenterol Clin. Biol. (1988) 12:80-81. French.
  • MOLDAWSKY RJ: Hepatotoxicity associated with maprotiline therapy: case report. 1 Clin. Psychiatry (1984) 45:178–179.
  • ALEEM A, LINGAM V: Hepatotoxicity following treatment with maprotiline. I Clin. Psychopharmacol (1987) 7:54–55.
  • WEINSTEIN RP, GOSSELIN JY: Case report of hepatotoxicity associated with maprotiline. Can. I Psychiatry (1988) 33:233–234.
  • TANAKA H, FURUSATO M, TAKASAKI S, WATANABE M, HATTORI Y: Morphological and biochemical alteration in the rat liver induced by maprotiline. Acta Pathol Jpn. (1975) 25:413–437.
  • BARBARE JC, BIOUR M, CADOT T, LATRIVE JP: [Hepatotoxicity of mianserin: a case with positive reintroduction]. Castroenterol Clin. Biol. (1992) 16:486-488. French.
  • OTANI K, KANEKI S, TASAKI H, FUKUSHIMA Y: Hepatic injury caused by mianserin. Br Med. J. (1989) 299:519.
  • RILEY RJ, MAGGS JL, LAMBERT C, KITTERINGHAM NR, PARK BK: An in vitro study of the microsomal metabolism and cellular toxicity of phenytoin, sorbinil and mianserin. Br. J. Clin. Pharmacol (1988) 26:577–588.
  • MORTON AR, YU R, WALDEK S, HOLMES AM, MUNDY K: Withdrawal of nomifensine. Br Med. 1 (1986) 293:452–453.
  • DANKBAAR H, MUDDE AH: Fever and liver function disorders caused by nomifensine. Ned. Tildschr. Cerieeskd. (1980) 124:2184–1286.
  • HU KQ, TIYYAGURA L, KANEL G, REDEKER AG: Acute hepatitis induced by bupropion. Dig. Dis. Sci. (2000) 45:1872–1873.
  • TUCKER WE Jr: Preclinical toxicology of bupropion: an overview. 1 Clin Psychiatry (1983) 44:60–62.
  • ZIMMERMAN HJ, MADDREY WC: Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology (1995) 22:767–773.
  • SEETO RK, FENN B, ROCKEY DC: Ischemic hepatitis: clinical presentation and pathogenesis. Am. 1 Med. (2000) 109:109–113.
  • OSLIN DW, DUFFY K: The risk of increased serum aminotransferases in a patient treated with bupropion. j Clin Psychopharmacol (1993) 13:364–365.
  • ALVARO D, ONETTI-MUDA A, MOSCATELLI R, ATILI AF: Acute cholestatic hepatitis induced by bupropion prescribed as pharmacological support to stop smoking. A case report. Dig. Liver Dis. (2001) 33:703–706.
  • AI-LENG K, LAI-SAN T, KANG-HOE L, GEK-KEE L: Acute liver failure with concurrent bupropion and carbimazole therapy. Ann. Pharmacother (2003) 37:220–223.
  • CHU AG, GUNSOLLY BL, SUMMERS RW et al.: Trazodone and liver toxicity. Ann. Intern. Med. (1983) 99:128–129.
  • SHEIKH KH, NIES AS: Trazodone and intrahepatic cholestasis. Ann. Intern. Med (1983) 99:572.
  • LONGSTRETH GF, HERSHMAN J: Trazodone-induced hepatotoxicity and leukonychia. 1 Am. Acad. Dermatol (1985) 13:149–150.
  • BECK PL, BRIDGES RJ, DEMETRICK DJ et al.: Chronic active hepatitis associated with trazodone therapy. Ann. Intern. Med. (1993) 118:791–792.
  • HULL M, JONES R, BENDALL M: Fatal hepatic necrosis associated with trazodone and neuroleptic drugs. Br. Med. 1. (1994) 309:378.
  • FERNANDES NF, MARTIN RR, SCHENKER S: Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. Am. 1 Castroenterol. (2000) 95:532–535.
  • YASUI N, OTANI K, KANEKO S et al.: Inhibition of trazodone metabolism of thioridazine in humans. Ther. Drug Montt. (1995) 17:333–335.
  • ARANDA-MICHEL J, KOEHLER A, BEJARANO PA et al: Nefazodone-induced liver failure: report of three cases. Ann. Intern. Med. (1999) 130:285–288.
  • LUCENA MI, ANDRADE RJ, GOMEZ-OUTES A et al: Acute liver failure after treatment with nefazodone. Dis. Sci. (1999) 44:2577–2579.
  • ELOUBEIDI MA, GAEDE JT, SWAIM MW: Reversible nefazodone-induced liver failure. Dis. Sci. (2000) 45:1036–1038.
  • FARRELL GC: Pathogenesis of drug-induced liver disease. In: AASLD Postgraduate Course. Liver injury update: clinical implications and mechanism role of cell of the liver. American Association for the Study of Liver Disease, Chicago, USA (1997):37–47.
  • DRESSER GK, SPENCE JD, BAILEY DG: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. CM]. Pharmacakinet. (2000) 38:41–57.
  • CARVAJAL A, GARCIA DEL POZO J, SANCHEZ-SANCHEZ A et al.: Hepatotoxicity associated with the new antidepressants. J. CM]. Psychiatry (2002) 63:135–137.
  • •A first estimate of the reported incidence of liver toxicity related to the most frequently used antidepressants.
  • HORSMANS Y, DE CLERCQ M, SEMPOUX C: Venlafaxine-associated hepatitis. Ann. Intern. Med (1999) 130:944.
  • CARDONA X, AVILA A, CASTELLANOS P: Venlafaxine-associated hepatitis. Ann. Intern. Med (2000) 132:417.
  • HUI CK, YUEN MF, WONG WM, LAM SK, LAI CL: Mirtazapine-induced hepatotoxicity. j CM]. Castraenteral (2002) 35:270–271.
  • GOODMAN ZD: Drug hepatotoxicity. CM]. Liver Dis. (2002) 6:381–397.
  • ALMDAL TP SORENSEN TIA: Incidence of parenchymal liver diseases in Denmark, 1981 to 1985: analysis of hospitalization registry data. The Danish Association for the Study of the Liver. Hepatalagy (1991) 13:650–655.
  • PI AP: A review of the common properties of drugs with idiosyncratic hepatotoxicity and the 'multiple determinant hypothesis' for the manifestation of idiosyncratic drug toxicity. Chem. Biol. Interact. (2002) 142:7–23.
  • ••An excellent review of the genetic andenvironmental mechanisms of drug hepatotoxicity and the ongoing research in this field to minimise the occurrence of this adverse reaction.
  • LARREY D, RUEFF B, PESSAYRE D: Cross hepatotoxicity between tricyclic antidepressants. Cut (1986) 27:726–727.
  • REMY AJ, LARREY D, PAGEAUX GP et al: Cross hepatotoxicity between tricyclic antidepressants and phenothiazines. Eur. Castraenteral. Hepatal. (1995) 7:373–376.
  • ANDRADE RJ, LUCENA MI, AGUILAR J et al.: Chronic liver injury related to use of bentazepam. An unusual instance of benzodiazepine hepatotoxicity. Dig. Dis. Li. (2000) 45:1400–1404.
  • HABERSETZER F, LARREY D, BABANY G et al: Clotiazepam-induced acute hepatitis. J. Hepatal (1989) 9:256–259.
  • ANDRADE RJ, LUCENA MI, ALCANTARA R, FRAILE JM: Bentazepam-associated chronic liver disease. Lancet (1994) 343:860.
  • PIZARRO AE, ANDRADE RJ, GARCIA-CORTES M et al.: [Acute hepatitis due to ticlopidine. A report of 12 cases and review of the literature]. Rev Neural (2001) 33:1014-1020. Spanish.
  • ZARSKI JP, AUBERT H, RACHAIL M: Toxicité hépatique des noveaux anti-dépresseurs. A propos dune observation. Castraenteral. Clir]. Biol. (1983) 7:16–17.
  • LEE WM: Drug-induced hepatotoxicity. N. Eng]. J. Med. (1995) 333:1118–1127.
  • LEWIS JH: The rational use of potentially hepatotoxic medications in patients with underlying liver disease. Expert Opin. Drug Sal: (2002) 1:159–172.
  • •An outstanding paper that offers a guide to the difficult issue of prescribing potentially harmful drugs in patients with diminished hepatic reserve.
  • SCHENKER S, MARTIN RR, HOYUMPA AM: Antecedent liver disease and drug toxicity. J. Hepatal. (1999) 31:1098–1105.
  • ANDRADE RJ, LUCENA MI, FERNANDEZ MC, VEGA JL, CAMARGO R: Hepatotoxicity in patients with cirrhosis, an often unrecognized problem. Lessons from a fatal case related to amoxicilliniclavulanic acid. Dig. Dis. Sci. (2001) 46:1416–1419.
  • LEVENSON JL, FALLON HJ: Fluoxetine treatment of depression caused by interferon-a. Am. J. Cast/venter-al. (1993) 88:760–761.
  • KRAUS MR, SCHAFER A, SCHEURLEN M: Paroxetine for the prevention of depression induced by interferon-a. N Engl. J. Med. (2001) 345:375–376.
  • SCHENKER S, BERGSTROM RF, WOLEN RL, LEMBERGER L: Fluoxetine disposition and elimination in cirrhosis. CM]. Pharmacy] Ther. (1988) 44:353–359.
  • ROWLAND M, TOZER TN: Clinical Pharmacakinetics Ord edn I Williams & Wilkins, Baltimore (1995).
  • ANDRADE RJ, LUCENA MI: Acute fulminant hepatitis after treatment with rabeprazole and terbinafine. Is rabeprazole the culprit? Arch. Intern. Med (2002) 162:360–361.
  • ANDRADE RJ, LUCENA MI, MARTIN-VIVALDI R et al.: Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J. Hepatal (1999) 31:641–646.
  • PHILLIPS KA, VEENSTRA DL, OREN E et al: Potential role of pharmacogenetics in reducing adverse drug reactions: a systemic review. JAMA (2001) 286:2270–2279.
  • KAPLOWITZ N: Drug-induced hepatocellular injury and cholestasis. In: AASLD Postgraduate Course. Mechanisms of acute and chronic liver diseases: implications for diagnosis, pathogenesis and treatment. American Association for the Study of Liver Disease, Boston, USA (2002):79–86.
  • BOHAN A, BOYER JL: Mechanisms of hepatic transport of drugs: implications for cholestatic drug reactions. Serail]. Liver Dis. (2002): 22:123–133.
  • ••An updated overview of the canalicularmembrane transporters in hepatocytes and their implications for drug-induced cholestasis.

Websites

  • http://www.fda.govicderilivertox CDER-PHRMA-AASLD Conference 2000: Drug-induced hepatotoxicity. White Paper.
  • http://www.fda.goviochfrmi riskmanagement.pdf NO AUTHORS LISTED: Managing the risks from medical product use: creating a risk management framework.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.